Marshall Wace
RNAC icon

Marshall Wace’s Cartesian Therapeutics RNAC Stock Holding History

Marshall Wace’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.54M Buy
251,115
+72,975
+41% +$520K ﹤0.01% 1926
2025
Q4 		$1.28M Buy
178,140
+93,334
+110% +$755K ﹤0.01% 1806
2025
Q3 		$867K Buy
84,806
+2,176
+3% +$24.5K ﹤0.01% 2001
2025
Q2 		$859K Buy
82,630
+44,025
+114% +$469K ﹤0.01% 1918
2025
Q1 		$509K Buy
+38,605
New +$690K ﹤0.01% 2072
2024
Q3 		– Sell
-30,038
Closed -$811K – 2892
2024
Q2 		$811K Buy
+30,038
New +$717K ﹤0.01% 1780
2023
Q2 		– Sell
-43,292
Closed -$1.81M – 2908
2023
Q1 		$1.81M Sell
43,292
-389
-0.9% -$18.3K ﹤0.01% 1506
2022
Q4 		$1.48M Sell
43,681
-17,955
-29% -$764K ﹤0.01% 1899
2022
Q3 		$3.03M Buy
61,636
+28,880
+88% +$1.59M 0.01% 1738
2022
Q2 		$1.29M Buy
32,756
+15,780
+93% +$468K ﹤0.01% 2293
2022
Q1 		$627K Sell
16,976
-49,410
-74% -$3.09M ﹤0.01% 2671
2021
Q4 		$6.49M Buy
+66,386
New +$7.14M 0.01% 1176
2021
Q3 		– Sell
-10,143
Closed -$1.27M – 3365
2021
Q2 		$1.27M Buy
+10,143
New +$1.21M 0.01% 1691
2020
Q4 		– Sell
-34,102
Closed -$2.54M – 2128
2020
Q3 		$2.54M Buy
+34,102
New +$2.61M 0.02% 749
2018
Q4 		– Sell
-850
Closed -$396K – 1776
2018
Q3 		$396K Buy
+850
New +$342K ﹤0.01% 972
2016
Q3 		– Sell
-1,207
Closed -$506K – 1109
2016
Q2 		$506K Buy
+1,207
New +$507K ﹤0.01% 824

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Marshall Wace's RNAC Position: Q1 2026 in Review

Marshall Wace increased its Cartesian Therapeutics (RNAC) stake by 41% in Q1 2026, buying an estimated $520K and bringing the position to 251,115 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1926.

Marshall Wace first reported a position in RNAC in Q2 2016 and has held it in 16 quarters since. The position peaked at $6.49M in Q4 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Marshall Wace held 251,115 shares of Cartesian Therapeutics worth $1.54M as of Q1 2026.
  • Marshall Wace bought 72,975 Cartesian Therapeutics shares in Q1 2026, an estimated $520K.
  • Cartesian Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1926 holding.
  • Marshall Wace first reported a position in Cartesian Therapeutics in Q2 2016 and has held it in 16 quarters since.
  • Marshall Wace's Cartesian Therapeutics position peaked at $6.49M in Q4 2021.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.